Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19

Faíco-Filho et al., Braz J Microbiol, doi:10.1007/s42770-020-00395-x (date from preprint)
Jun 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Δt7-12 ΔCt improvement 81% Improvement Relative Risk Δt<7 ΔCt improvement 24% Δt>12 ΔCt improvement -15% HCQ for COVID-19  Faíco-Filho et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Prospective study of 66 patients in Brazil Improved viral reduction rate with HCQ (not stat. sig., p=0.4) c19hcq.org Faíco-Filho et al., Braz J Microbiol, Jun 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Viral load comparison for 34 HCQ and 32 control patients hospitalized with moderate COVID-19. All patients recovered limiting the room for beneficial effects.
While not achieving statistical significance, results show faster recovery with HCQ. The greatest benefit is seen mid-recovery as expected for an effective treatment:
Δt7-12: 81% improvement with HCQ
Δt<7: 24% improvement with HCQ
For Δt>12, everyone has recovered so there is no room for improvement. Since the HCQ group started slightly higher the improvement is slightly less. Most participants have also dropped out by this test, with only 6 HCQ and 9 control remaining (also suggesting HCQ patients recovered faster).
Δt7-12 ΔCt improvement, 80.8% lower, RR 0.19, p = 0.40, treatment 34, control 32, mid-recovery, relative median Ct improvement, Figure 2.
Δt<7 ΔCt improvement, 24.0% lower, RR 0.76, p = 0.36, treatment 34, control 32, relative median Ct improvement, Figure 2.
Δt>12 ΔCt improvement, 15.0% higher, RR 1.15, p = 0.52, treatment 34, control 32, relative median Ct improvement, Figure 2.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Faíco-Filho et al., 21 Jun 2020, prospective, Brazil, peer-reviewed, median age 58.0, 6 authors.
This PaperHCQAll
No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19
Klinger Soares Faíco-Filho, Danielle Dias Conte, Luciano Kleber De Souza Luna, Joseane Mayara Almeida Carvalho, Ana Helena Sitta Perosa, Nancy Bellei
Brazilian Journal of Microbiology, doi:10.1007/s42770-020-00395-x
Background Some studies have shown that hydroxychloroquine (HCQ) is an effective drug in reducing the in vitro replication of SARS-CoV-2. However, the in vivo effect of HCQ still unclear. Objectives This study aims to evaluate viral load clearance in patients with COVID-19 who underwent HCQ treatment in comparison with a control group that did not receive the drug. Study design This prospective study comprised consecutive viral load measurements in patients with COVID-19 hospitalized with a moderate illness. Patients received 400 mg of HCQ every 12 h for 10 days according to the medical decision. Nasal swab samples were collected from patients during early, intermediary, and final clinical stage of COVID-19. Results A total of 155 samples were collected from 66 patients with COVID-19 (60% female), with a median age of 58 years. The viral load between studied groups, assumed as a semiquantitative measure of cycle threshold (Ct) values, presented no significant difference within the three consecutive measures (ΔCt) (p > 0.05). We also analyzed the ΔCt viral load at different intervals of sample collection (Δt < 7; 7-12; and > 12 days) without significant differences at any ΔCt (p > 0.05). Conclusion In this study, we did not observe any change in viral load reduction in vivo with the use of HCQ.
References
Andreani, Bideau, Duflot, Jardot, Rolland et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog
Cdc, CDC 2019-Novel Coronavirus (2019-nCoV) Realtime RT-PCR diagnostic panel
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Engl J Med
Lescure, Bouadma, Nguyen, Parisey, Wicky et al., Clinical and virological data of the first cases of COVID-19 in Europe: a case series, Lancet Infect Dis
Lim, Jeon, Shin, Kim, Seong et al., Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR, J Korean Med Sci
Liu, Yan, Wan, Xiang, Le et al., Viral dynamics in mild and severe cases of COVID-19, Lancet Infect Dis
Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: a single center experience, J Med Virol
Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis
Thachil, The versatile heparin in COVID-19, J Thromb Haemost
Torjesen, Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds, BMJ: British Medical Journal (Online)
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Who, Coronavirus disease 2019 (COVID-19)
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci
Yan, Zou, Sun, Li, Xu et al., Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zheng, Yu, Feng, Lou, Zou, Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January, BMJ
Zou, Ruan, Huang, Liang, Huang et al., SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N Engl J Med
{ 'indexed': {'date-parts': [[2023, 4, 3]], 'date-time': '2023-04-03T12:19:29Z', 'timestamp': 1680524369647}, 'reference-count': 18, 'publisher': 'Springer Science and Business Media LLC', 'issue': '4', 'license': [ { 'start': { 'date-parts': [[2020, 10, 27]], 'date-time': '2020-10-27T00:00:00Z', 'timestamp': 1603756800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2020, 10, 27]], 'date-time': '2020-10-27T00:00:00Z', 'timestamp': 1603756800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1007/s42770-020-00395-x', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 27]], 'date-time': '2020-10-27T20:13:55Z', 'timestamp': 1603829635000}, 'page': '1765-1769', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 4, 'title': 'No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized ' 'patients with COVID-19', 'prefix': '10.1007', 'volume': '51', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-2071-0061', 'authenticated-orcid': False, 'given': 'Klinger Soares', 'family': 'Faíco-Filho', 'sequence': 'first', 'affiliation': []}, {'given': 'Danielle Dias', 'family': 'Conte', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Luciano Kleber', 'family': 'de Souza Luna', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Joseane Mayara Almeida', 'family': 'Carvalho', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ana Helena Sitta', 'family': 'Perosa', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nancy', 'family': 'Bellei', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 10, 27]]}, 'reference': [ { 'key': '395_CR1', 'unstructured': 'WHO(2020). Coronavirus disease 2019 (COVID-19), Situation Report – 51. ' 'World Health Organization'}, { 'key': '395_CR2', 'doi-asserted-by': 'publisher', 'first-page': '101663', 'DOI': '10.1016/j.tmaid.2020.101663', 'volume': '34', 'author': 'P Gautret', 'year': '2020', 'unstructured': 'Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe ' 'M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, ' 'Vieira VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, la ' 'Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain ' 'JM, Brouqui P, Raoult D (2020) Clinical and microbiological effect of a ' 'combination of hydroxychloroquine and azithromycin in 80 COVID-19 ' 'patients with at least a six-day follow up: a pilot observational study. ' 'Travel Med Infect Dis 34:101663', 'journal-title': 'Travel Med Infect Dis'}, { 'key': '395_CR3', 'doi-asserted-by': 'publisher', 'first-page': '814', 'DOI': '10.1002/jmv.25801', 'volume': '92', 'author': 'P Luo', 'year': '2020', 'unstructured': 'Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J (2020) Tocilizumab treatment in ' 'COVID-19: a single center experience. J Med Virol 92:814–818', 'journal-title': 'J Med Virol'}, { 'key': '395_CR4', 'doi-asserted-by': 'publisher', 'first-page': '10970', 'DOI': '10.1073/pnas.2005615117', 'volume': '117', 'author': 'X Xu', 'year': '2020', 'unstructured': 'Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, ' 'Zhang X, Pan A, Wei H (2020) Effective treatment of severe COVID-19 ' 'patients with tocilizumab. Proc Natl Acad Sci U S A 117:10970–10975', 'journal-title': 'Proc Natl Acad Sci U S A'}, { 'key': '395_CR5', 'doi-asserted-by': 'publisher', 'first-page': '269', 'DOI': '10.1038/s41422-020-0282-0', 'volume': '30', 'author': 'M Wang', 'year': '2020', 'unstructured': 'Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao ' 'G (2020) Remdesivir and chloroquine effectively inhibit the recently ' 'emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271', 'journal-title': 'Cell Res'}, { 'key': '395_CR6', 'doi-asserted-by': 'publisher', 'first-page': '1020', 'DOI': '10.1111/jth.14821', 'volume': '18', 'author': 'J Thachil', 'year': '2020', 'unstructured': 'Thachil J (2020) The versatile heparin in COVID-19. J Thromb Haemost ' '18:1020–1022', 'journal-title': 'J Thromb Haemost'}, { 'key': '395_CR7', 'doi-asserted-by': 'publisher', 'first-page': '67', 'DOI': '10.1016/S1473-3099(06)70361-9', 'volume': '6', 'author': 'A Savarino', 'year': '2006', 'unstructured': 'Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A (2006) New ' 'insights into the antiviral effects of chloroquine. Lancet Infect Dis ' '6:67–69', 'journal-title': 'Lancet Infect Dis'}, { 'key': '395_CR8', 'doi-asserted-by': 'publisher', 'first-page': '300', 'DOI': '10.1038/cr.2012.165', 'volume': '23', 'author': 'Y Yan', 'year': '2013', 'unstructured': 'Yan Y, Zou Z, Sun Y, Li X, Xu KF, Wei Y, Jin N, Jiang C (2013) ' 'Anti-malaria drug chloroquine is highly effective in treating avian ' 'influenza A H5N1 virus infection in an animal model. Cell Res 23:300–302', 'journal-title': 'Cell Res'}, { 'key': '395_CR9', 'doi-asserted-by': 'publisher', 'first-page': '104228', 'DOI': '10.1016/j.micpath.2020.104228', 'volume': '145', 'author': 'J Andreani', 'year': '2020', 'unstructured': 'Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M et ' 'al (2020) In vitro testing of combined hydroxychloroquine and ' 'azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog ' '145:104228', 'journal-title': 'Microb Pathog'}, { 'key': '395_CR10', 'doi-asserted-by': 'publisher', 'first-page': '732', 'DOI': '10.1093/cid/ciaa237', 'volume': '71', 'author': 'X Yao', 'year': '2020', 'unstructured': 'Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song ' 'C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity ' 'and projection of optimized dosing design of hydroxychloroquine for the ' 'treatment of severe acute respiratory syndrome coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis 71:732–739', 'journal-title': 'Clin Infect Dis'}, { 'key': '395_CR11', 'doi-asserted-by': 'publisher', 'first-page': '2411', 'DOI': '10.1056/NEJMoa2012410', 'volume': '382', 'author': 'J Geleris', 'year': '2020', 'unstructured': 'Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G et al (2020) ' 'Observational study of hydroxychloroquine in hospitalized patients with ' 'Covid-19. N Engl J Med 382:2411–2418', 'journal-title': 'N Engl J Med'}, { 'key': '395_CR12', 'doi-asserted-by': 'publisher', 'first-page': 'm2263', 'DOI': '10.1136/bmj.m2263', 'volume': '369', 'author': 'I Torjesen', 'year': '2020', 'unstructured': 'Torjesen I (2020) Covid-19: Hydroxychloroquine does not benefit ' 'hospitalised patients, UK trial finds. BMJ: British Medical Journal ' '(Online) 369:m2263', 'journal-title': 'BMJ: British Medical Journal'}, { 'key': '395_CR13', 'unstructured': 'CDC. (2020) CDC 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR ' 'diagnostic panel. Centers for Disease Control and Prevention'}, { 'key': '395_CR14', 'doi-asserted-by': 'publisher', 'DOI': '10.3346/jkms.2020.35.e79', 'volume': '35', 'author': 'J Lim', 'year': '2020', 'unstructured': 'Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, Choe KW, Kang YM, Lee ' 'B, Park SJ (2020) Case of the index patient who caused tertiary ' 'transmission of COVID-19 infection in Korea: the application of ' 'lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia ' 'monitored by quantitative RT-PCR. J Korean Med Sci 35:e79', 'journal-title': 'J Korean Med Sci'}, { 'key': '395_CR15', 'doi-asserted-by': 'publisher', 'first-page': 'm1443', 'DOI': '10.1136/bmj.m1443', 'volume': '369', 'author': 'S Zheng', 'year': '2020', 'unstructured': 'Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q et al (2020) Viral load ' 'dynamics and disease severity in patients infected with SARS-CoV-2 in ' 'Zhejiang province, China, January-March 2020: retrospective cohort ' 'study. BMJ. 369:m1443', 'journal-title': 'BMJ.'}, { 'key': '395_CR16', 'doi-asserted-by': 'publisher', 'first-page': '1177', 'DOI': '10.1056/NEJMc2001737', 'volume': '382', 'author': 'L Zou', 'year': '2020', 'unstructured': 'Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, ' 'Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (2020) SARS-CoV-2 ' 'viral load in upper respiratory specimens of infected patients. N Engl J ' 'Med 382:1177–1179', 'journal-title': 'N Engl J Med'}, { 'key': '395_CR17', 'doi-asserted-by': 'publisher', 'first-page': '697', 'DOI': '10.1016/S1473-3099(20)30200-0', 'volume': '20', 'author': 'FX Lescure', 'year': '2020', 'unstructured': 'Lescure FX, Bouadma L, Nguyen D, Parisey M, Wicky PH, Behillil S, ' 'Gaymard A, Bouscambert-Duchamp M, Donati F, le Hingrat Q, Enouf V, ' 'Houhou-Fidouh N, Valette M, Mailles A, Lucet JC, Mentre F, Duval X, ' 'Descamps D, Malvy D, Timsit JF, Lina B, van-der-Werf S, Yazdanpanah Y ' '(2020) Clinical and virological data of the first cases of COVID-19 in ' 'Europe: a case series. Lancet Infect Dis 20:697–706', 'journal-title': 'Lancet Infect Dis'}, { 'key': '395_CR18', 'doi-asserted-by': 'publisher', 'first-page': '656', 'DOI': '10.1016/S1473-3099(20)30232-2', 'volume': '20', 'author': 'Y Liu', 'year': '2020', 'unstructured': 'Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM et al (2020) Viral dynamics ' 'in mild and severe cases of COVID-19. Lancet Infect Dis 20:656–657', 'journal-title': 'Lancet Infect Dis'}], 'container-title': 'Brazilian Journal of Microbiology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s42770-020-00395-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s42770-020-00395-x/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s42770-020-00395-x.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 10, 26]], 'date-time': '2021-10-26T23:15:35Z', 'timestamp': 1635290135000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s42770-020-00395-x'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 27]]}, 'references-count': 18, 'journal-issue': {'issue': '4', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['395'], 'URL': 'http://dx.doi.org/10.1007/s42770-020-00395-x', 'relation': {}, 'ISSN': ['1517-8382', '1678-4405'], 'subject': [ 'Microbiology', 'Computer Networks and Communications', 'Hardware and Architecture', 'Software'], 'container-title-short': 'Braz J Microbiol', 'published': {'date-parts': [[2020, 10, 27]]}, 'assertion': [ { 'value': '4 August 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '21 October 2020', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '27 October 2020', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit